IL134643A0 - Chimeric transcriptional activators and compositions and uses related thereto - Google Patents

Chimeric transcriptional activators and compositions and uses related thereto

Info

Publication number
IL134643A0
IL134643A0 IL13464397A IL13464397A IL134643A0 IL 134643 A0 IL134643 A0 IL 134643A0 IL 13464397 A IL13464397 A IL 13464397A IL 13464397 A IL13464397 A IL 13464397A IL 134643 A0 IL134643 A0 IL 134643A0
Authority
IL
Israel
Prior art keywords
compositions
transcriptional activators
uses related
chimeric transcriptional
chimeric
Prior art date
Application number
IL13464397A
Original Assignee
Ariad Gene Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ariad Gene Therapeutics Inc filed Critical Ariad Gene Therapeutics Inc
Publication of IL134643A0 publication Critical patent/IL134643A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1055Protein x Protein interaction, e.g. two hybrid selection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67General methods for enhancing the expression

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL13464397A 1997-08-27 1997-08-27 Chimeric transcriptional activators and compositions and uses related thereto IL134643A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1997/015219 WO1999010508A1 (en) 1997-08-27 1997-08-27 Chimeric transcriptional activators and compositions and uses related thereto

Publications (1)

Publication Number Publication Date
IL134643A0 true IL134643A0 (en) 2001-04-30

Family

ID=22261527

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13464397A IL134643A0 (en) 1997-08-27 1997-08-27 Chimeric transcriptional activators and compositions and uses related thereto

Country Status (6)

Country Link
EP (1) EP1003886A1 (en)
JP (1) JP2001514007A (en)
AU (1) AU752129B2 (en)
CA (1) CA2303482A1 (en)
IL (1) IL134643A0 (en)
WO (1) WO1999010508A1 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1194544A1 (en) * 1999-06-18 2002-04-10 Ariad Gene Therapeutics, Inc. Chimeric oca-b transcription factors
CA2398010A1 (en) 2000-01-24 2001-07-26 The Trustees Of Columbia University In The City Of New York An in vivo screen using chemical inducers of dimerization
AU2001241682A1 (en) * 2000-02-24 2001-09-03 The Salk Institute For Biological Studies Gene expression system based on chimeric receptors
EP1290196A1 (en) * 2000-06-16 2003-03-12 Ariad Gene Therapeutics, Inc. Chimeric hsf transcription factors
AU2002247214B2 (en) * 2001-02-20 2008-04-03 Intrexon Corporation Chimeric retinoid X receptors and their use in a novel ecdysone receptor-based inducible gene expression system
US8735153B2 (en) 2001-09-24 2014-05-27 Sangamo Biosciences, Inc. Modulation of stem cells using zinc finger proteins
US7083918B2 (en) 2002-04-24 2006-08-01 The Trustees Of Columbia University In The City Of New York Bacterial small-molecule three-hybrid system
US7407776B2 (en) 2003-09-19 2008-08-05 Sangamo Biosciences, Inc. Engineered zinc finger proteins for regulation of gene expression
US20060063231A1 (en) 2004-09-16 2006-03-23 Sangamo Biosciences, Inc. Compositions and methods for protein production
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
KR20130040844A (en) 2010-03-29 2013-04-24 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Pharmacologically induced transgene ablation system
US20140031418A1 (en) 2011-04-20 2014-01-30 The Trustees Of The University Of Pennsylvania Regimens and Compositions for AAV-Mediated Passive Immunization of Airborne Pathogens
AU2016275909A1 (en) 2015-05-13 2017-11-09 The Trustees Of The University Of Pennsylvania AAV-mediated expression of anti-influenza antibodies and methods of use thereof
EP3452103A1 (en) 2016-04-15 2019-03-13 The Trustees Of The University Of Pennsylvania Compositions for treatment of wet age-related macular degeneration
ES2971872T3 (en) 2017-02-28 2024-06-10 Univ Pennsylvania Adeno-associated virus (AAV) clade F vector and uses for the same
JOP20190200A1 (en) 2017-02-28 2019-08-27 Univ Pennsylvania Compositions useful in treatment of spinal muscular atrophy
BR112019017697A2 (en) 2017-02-28 2020-04-07 Janssen Biotech Inc influenza vaccines based on adeno-associated virus (aav) vectors
CA3079568A1 (en) 2017-10-18 2019-04-25 Regenxbio Inc. Fully-human post-translationally modified antibody therapeutics
MX2020003945A (en) 2017-10-18 2020-11-09 Regenxbio Inc Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified vegf-trap.
AU2020253462A1 (en) 2019-04-03 2021-10-28 Regenxbio Inc. Gene therapy for eye pathologies
WO2020219868A1 (en) 2019-04-24 2020-10-29 Regenxbio Inc. Fully-human post-translationally modified antibody therapeutics
WO2021041373A1 (en) 2019-08-26 2021-03-04 Regenxbio Inc. Treatment of diabetic retinopathy with fully-human post-translationally modified anti-vegf fab
EP4041292A1 (en) 2019-10-07 2022-08-17 RegenxBio Inc. Adeno-associated virus vector pharmaceutical composition and methods
WO2022060915A1 (en) 2020-09-15 2022-03-24 Regenxbio Inc. Vectorized lanadelumab and administration thereof
WO2022060916A1 (en) 2020-09-15 2022-03-24 Regenxbio Inc. Vectorized antibodies for anti-viral therapy
KR20230083287A (en) 2020-10-07 2023-06-09 리젠엑스바이오 인크. Gene therapy for ocular manifestations of CLN2 disease
WO2022094157A1 (en) 2020-10-28 2022-05-05 Regenxbio Inc. Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof
MX2023004806A (en) 2020-10-28 2023-05-10 Regenxbio Inc Vectorized anti-tnf-î± antibodies for ocular indications.
MX2023004843A (en) 2020-10-29 2023-05-10 Regenxbio Inc Vectorized tnf-alpha antagonists for ocular indications.
US20230390418A1 (en) 2020-10-29 2023-12-07 Regenxbio Inc. Vectorized factor xii antibodies and administration thereof
AR124216A1 (en) 2020-12-01 2023-03-01 Univ Pennsylvania NEW COMPOSITIONS WITH TISSUE-SPECIFIC SELECTIVE MOTIFS AND COMPOSITIONS CONTAINING THEM
CN112661820B (en) * 2020-12-31 2021-12-14 中国科学院天津工业生物技术研究所 Rhizobium tianshanense transcription regulation protein MsiR mutant protein and application thereof in canavanine biosensor
BR112023021971A2 (en) 2021-04-23 2024-02-20 Univ Pennsylvania COMPOSITIONS WITH BRAIN-SPECIFIC DIRECTION MOTIFS AND COMPOSITIONS CONTAINING THE SAME
TW202325845A (en) 2021-10-02 2023-07-01 賓州大學委員會 Novel aav capsids and compositions containing same
AU2023211652A1 (en) 2022-01-25 2024-08-08 The Trustees Of The University Of Pennsylvania Aav capsids for improved heart transduction and detargeting of liver
WO2023201308A1 (en) 2022-04-14 2023-10-19 Regenxbio Inc. Gene therapy for treating an ocular disease
WO2023205610A2 (en) 2022-04-18 2023-10-26 Regenxbio Inc. Hybrid aav capsids
WO2023215807A1 (en) 2022-05-03 2023-11-09 Regenxbio Inc. VECTORIZED ANTI-TNF-α INHIBITORS FOR OCULAR INDICATIONS
TW202400803A (en) 2022-05-03 2024-01-01 美商銳進科斯生物股份有限公司 Vectorized anti-complement antibodies and complement agents and administration thereof
CN117467020A (en) * 2022-07-29 2024-01-30 南京百斯杰生物工程有限公司 Chimeric transcription activator and application thereof
WO2024073669A1 (en) 2022-09-30 2024-04-04 Regenxbio Inc. Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2053197A (en) * 1996-02-23 1997-09-10 Ariad Pharmaceuticals, Inc. Cell-based assay
WO1997044447A2 (en) * 1996-05-03 1997-11-27 President And Fellows Of Harvard College Transcriptional activation system, activators, and uses therefor

Also Published As

Publication number Publication date
CA2303482A1 (en) 1999-03-04
AU4240297A (en) 1999-03-16
EP1003886A1 (en) 2000-05-31
JP2001514007A (en) 2001-09-11
AU752129B2 (en) 2002-09-05
WO1999010508A1 (en) 1999-03-04

Similar Documents

Publication Publication Date Title
IL134643A0 (en) Chimeric transcriptional activators and compositions and uses related thereto
HUP0001154A3 (en) 3-piperidyl-4-oxoquinazoline derivatives and medicincal compositions containing the same
ZA985096B (en) Composition compound and use
EP0965321A4 (en) Composition for external use
GB9717598D0 (en) Novel composition and use
GB9704524D0 (en) Composition
GB9715203D0 (en) Composition
GB9711683D0 (en) Composition
HU9800596D0 (en) Antifungal compositions and use thereof
GB9715489D0 (en) Composition
GB9714010D0 (en) Composition
GB9726777D0 (en) Composition
EP0958806A4 (en) Haircoloring composition
GB9714359D0 (en) Composition
GB9718636D0 (en) Novel composition and use
GB9724975D0 (en) Composition
GB9722392D0 (en) Composition and use
GB9726811D0 (en) Compounds compositions and use
GB9705110D0 (en) Composition
GB9716805D0 (en) Novel composition and use
GB9719203D0 (en) Novel composition and use
GB9712961D0 (en) Composition and use
GB9722390D0 (en) Composition and use
GB9706758D0 (en) Compositions and their use
HUP9904337A3 (en) Polyester compositions